Orrick Advises Third Rock Ventures and Lightspeed Venture Partners on Investment in Abata Therapeutics’ $95 Million Series A


We have advised lead investor Third Rock Ventures, as well as Lightspeed Venture Partners, on their investment in Abata Therapeutics’ $95 million Series A financing round. ElevateBio, Invus, Samsara BioCapital and the JDRF T1D Fund also participated in the round. The Orrick team was led by Gregg Griner and included Chris Reynolds and Jenée Iyer.